-ertinib
An EGFR inhibitor, blocking the epidermal growth factor receptor; mostly lung cancer drugs.
- Drugs ending in -ertinib: 20
- Approved somewhere: 3
- With a US drug page: 6
- Stem
- -ertinib
- Class
- Drugs that block the EGFR growth-factor receptor
- Sub-stem of
- -tinib: Small molecules that block tyrosine kinases, the switches for many growth signals
Approved and clinical-stage drugs in ChEMBL whose names ending in -ertinib, matched by spelling; those with a US drug page link to it.
| Acts on | |||
|---|---|---|---|
| Lazertinib | Approved | EGFR | Epidermal growth factor receptor erbB1 inhibitor |
| Mobocertinib | Approved | EGFR | Epidermal growth factor receptor erbB1 inhibitor |
| Osimertinib | Approved | EGFR | Epidermal growth factor receptor erbB1 inhibitor |
| Sunvozertinib | Phase 3 | — | — |
| Sevabertinib | Phase 2 | — | — |
| Zongertinib | Phase 1 | — | — |
| Abivertinib | Phase 3 | EGFR, BTK | Epidermal growth factor receptor erbB1 inhibitor |
| Aumolertinib | Phase 3 | EGFR | Epidermal growth factor receptor erbB1 inhibitor |
| Firmonertinib | Phase 3 | EGFR | Epidermal growth factor receptor erbB1 inhibitor |
| Rezivertinib | Phase 3 | — | — |
| Befotertinib | Phase 2 | — | — |
| Canertinib | Phase 2 | EGFR, ERBB2, ERBB4 | Epidermal growth factor receptor erbB1 inhibitor |
| Mifanertinib | Phase 2 | — | — |
| Sacibertinib | Phase 2 | — | — |
| Tigozertinib | Phase 2 | — | — |
| Ulixertinib | Phase 2 | MAPK3, MAPK1 | MAP kinase ERK1 inhibitor |
| Mavelertinib | Phase 1 | EGFR | Epidermal growth factor receptor erbB1 inhibitor |
| Pebezertinib | Phase 1 | — | — |
| Ravoxertinib | Phase 1 | MAPK3, MAPK1 | MAP kinase ERK1 inhibitor |
| Tuxobertinib | Phase 1 | ERBB2, EGFR | Receptor protein-tyrosine kinase erbB-2 negative allosteric modulator |
Stem from WHO, The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances (2024); description written by Arca. Drugs, stages, targets and mechanisms from ChEMBL (CC BY-SA 3.0). WHO